Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
2009; Lippincott Williams & Wilkins; Volume: 182; Issue: 1 Linguagem: Inglês
10.1016/j.juro.2009.02.119
ISSN1527-3792
AutoresMarie Paule Sablin, S. Négrier, Alain Ravaud, Stéphane Oudard, Corinne Balleyguier, Julien Gautier, Chantal Célier, Jacques Médioni, Bernard Escudier,
Tópico(s)Cancer Genomics and Diagnostics
ResumoNo AccessJournal of UrologyAdult Urology1 Jul 2009Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma M.P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni, and B. Escudier M.P. SablinM.P. Sablin Institut Gustave Roussy, Villejuif, France , S. NegrierS. Negrier Centre Léon Bérard, Lyon, France , A. RavaudA. Ravaud Hôpital Saint-André, Bordeaux, France , S. OudardS. Oudard Hôpital Européen Georges Pompidou, Paris, France , C. BalleyguierC. Balleyguier Institut Gustave Roussy, Villejuif, France , J. GautierJ. Gautier Centre Léon Bérard, Lyon, France , C. CelierC. Celier Hôpital Saint-André, Bordeaux, France , J. MedioniJ. Medioni Hôpital Européen Georges Pompidou, Paris, France , and B. EscudierB. Escudier Institut Gustave Roussy, Villejuif, France View All Author Informationhttps://doi.org/10.1016/j.juro.2009.02.119AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Sorafenib and sunitinib are 2 tyrosine kinase inhibitors that were recently approved for renal cell carcinoma. In many patients sequential administration of the 2 drugs occurs because of the lack of sustained efficacy of the first agent. We determined the efficacy and safety of sequential administration. Materials and Methods: To determine whether cross-resistance occurs between these 2 drugs we analyzed the outcome in 90 consecutive patients with renal cell carcinoma from 4 sites in France who had received the 2 drugs sequentially. All patients received sorafenib followed by sunitinib or vice versa. From 2003 to 2006, 68 patients received sorafenib, while 22 received sunitinib first. Results: In the sorafenib-sunitinib group median progression-free survival was 26 weeks with sorafenib and 28 with sunitinib. In the sunitinib-sorafenib group median progression-free survival was 22 weeks with sunitinib and 17 with sorafenib. Median overall survival was 135 weeks in the sorafenib-sunitinib group and 82 weeks in the sunitinib-sorafenib group (HR 0.49, 95% CI 0.16 to 0.96, p = 0.04). The average duration of sequential administration was 61 and 49 weeks, respectively, in the sorafenib-sunitinib and sunitinib-sorafenib groups. Each sequence was well tolerated and no increase in grade 3-4 toxicity was observed. Conclusions: Overall this retrospective study supports the conclusion of the lack of absolute cross-resistance between tyrosine kinase inhibitors. In this renal cell carcinoma population sorafenib followed by sunitinib was associated with longer survival than sunitinib followed by sorafenib. However, this observation needs further confirmation. References 1 : Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med2007; 356: 125. Google Scholar 2 : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med2007; 356: 115. Google Scholar 3 : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med2007; 356: 2271. Google Scholar 4 : Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007; 370: 2103. Google Scholar 5 : Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol1995; 22: 42. Google Scholar 6 : Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med1998; 338: 1272. Google Scholar 7 : Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet1994; 7: 85. Google Scholar 8 : Overall survival with sunitinib versus interferon (IFN)-alfa as first line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol2008; 26. abstract 5024. Google Scholar 9 Escudier B: Overvew of clinical trials in RCC. Presented at European Society for Medical Oncology Congress, Stockholm, Sweden, September 12–16, 2008. Google Scholar 10 : New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000; 92: 205. Google Scholar 11 : Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol1999; 17: 2530. Google Scholar 12 : In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res2003; 9: 327. Google Scholar 13 : BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res2004; 64: 7099. Google Scholar 14 : Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol2007; 25: 18S. abstract 5106. Google Scholar 15 : Evaluation of VEGF targeted therapy efficacy in mRCC after sorafenib failure or intolerance. J Clin Oncol2007; 25: 18S. abstract 15517. Google Scholar 16 : Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol2008; 179: 81. Link, Google Scholar 17 : Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. Clin Genitourin Cancer2006; 5: 78. Google Scholar 18 : Use of von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). J Clin Oncol2009; 25: 18S. abstract 5012. Google Scholar 19 : Efficacy and safety of sunitinib malate in bevacizumab-refractory metastatic renal cell carcinoma (RCC). J Clin Oncol2006; 24: 18S. abstract 4522. Google Scholar 20 : Axitinib (AG013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol2007; 25: 18S. abstract 5032. Google Scholar © 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited byLaguna M (2018) Re: Tivozanib versus Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma: Results from a Phase III TrialJournal of Urology, VOL. 192, NO. 4, (1079-1079), Online publication date: 1-Oct-2014. Volume 182Issue 1July 2009Page: 29-34 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsrenal cellsorafenibkidneysunitinibdrug resistancecarcinomaAcknowledgmentsJ. Balcaceres and L. Bouaita assisted with data collection, and S. Charnick assisted with manuscript preparation.MetricsAuthor Information M.P. Sablin Institut Gustave Roussy, Villejuif, France More articles by this author S. Negrier Centre Léon Bérard, Lyon, France More articles by this author A. Ravaud Hôpital Saint-André, Bordeaux, France More articles by this author S. Oudard Hôpital Européen Georges Pompidou, Paris, France More articles by this author C. Balleyguier Institut Gustave Roussy, Villejuif, France More articles by this author J. Gautier Centre Léon Bérard, Lyon, France More articles by this author C. Celier Hôpital Saint-André, Bordeaux, France More articles by this author J. Medioni Hôpital Européen Georges Pompidou, Paris, France More articles by this author B. Escudier Institut Gustave Roussy, Villejuif, France More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)